Brighton Jones LLC Has $1.22 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Brighton Jones LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,137 shares of the company’s stock after selling 1,039 shares during the period. Brighton Jones LLC’s holdings in Novo Nordisk A/S were worth $1,216,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Montecito Bank & Trust increased its holdings in Novo Nordisk A/S by 17.1% in the 4th quarter. Montecito Bank & Trust now owns 3,861 shares of the company’s stock valued at $332,000 after buying an additional 565 shares during the period. Cerro Pacific Wealth Advisors LLC increased its stake in Novo Nordisk A/S by 33.5% in the fourth quarter. Cerro Pacific Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $284,000 after acquiring an additional 828 shares during the period. Apeiron RIA LLC raised its position in Novo Nordisk A/S by 25.3% in the fourth quarter. Apeiron RIA LLC now owns 5,935 shares of the company’s stock worth $510,000 after purchasing an additional 1,199 shares in the last quarter. Verde Capital Management lifted its stake in Novo Nordisk A/S by 115.6% during the fourth quarter. Verde Capital Management now owns 23,904 shares of the company’s stock worth $2,056,000 after purchasing an additional 12,815 shares during the period. Finally, Red Door Wealth Management LLC boosted its holdings in Novo Nordisk A/S by 167.3% during the fourth quarter. Red Door Wealth Management LLC now owns 9,608 shares of the company’s stock valued at $826,000 after purchasing an additional 6,013 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 8.4 %

NVO opened at $87.94 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The stock has a market capitalization of $394.65 billion, a PE ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $95.62 and a two-hundred day moving average price of $115.55.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NVO shares. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.